• Vaccine Name: GI24-lysed Brucella abortus cells vaccine candidate
• Target Pathogen: Brucella spp.
• Target Disease: Brucellosis
• Vaccine Ontology ID: VO_0009416
• Type: Inactivated vaccine
• Status: Research
• Host Species for Licensed Use: Goat
• Host Species as Laboratory Animal Model: Capra hircus (Korean black goats)
• Antigen: GI24 (bacteriophage lysis gene E)
• Preparation: The vaccine consisted of approximately 3 × 10^9 GI24-lysed Brucella abortus cells administered subcutaneously. (Kim et al, 2019)
• Description: The study evaluated the efficacy of a vaccine candidate composed of Brucella abortus cells lysed by GI24 as a potential vaccine against brucellosis in Korean black goats. Efficacy: Three of five goats immunized with the GI24-lysed vaccine were completely protected against challenge. Group B showed significantly lower infection index and tissue colonization compared to controls. Immune response: Immunized goats showed significantly higher ELISA optical density values for B. abortus lipopolysaccharide and elevated cytokine levels (IL-4, TNF-α, IFN-γ) compared to controls, indicating a strong immune response without adverse clinical effects. (Kim et al, 2019)

Goat Response

• Immune Response: Immunized goats showed significantly higher ELISA optical density values for B. abortus lipopolysaccharide and elevated cytokine levels (IL-4, TNF-α, IFN-γ) compared to controls, indicating a strong immune response without adverse clinical effects. (Kim et al, 2019)
• Challenge Protocol: Protective efficacy was assessed by intraconjunctival challenge with B. abortus strain 544 and subsequent evaluation of infection index and tissue colonization. (Kim et al, 2019)
• Efficacy: Three of five goats immunized with the GI24-lysed vaccine were completely protected against challenge. Group B showed significantly lower infection index and tissue colonization compared to controls. (Kim et al, 2019)
• Description: Two groups of Korean black goats were immunized subcutaneously; group B received the lysed cells vaccine, and group A received sterile phosphate-buffered saline as control. Immune responses were measured by ELISA for B. abortus lipopolysaccharide antibodies and cytokine levels (IL-4, TNF-α, IFN-γ). Protective efficacy was assessed by intraconjunctival challenge with B. abortus strain 544 and subsequent evaluation of infection index and tissue colonization. (Kim et al, 2019)